Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for Comorbid Obesity and Stimulant Use Disorder (TRI-MR)
NCT07693608Phase 2Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Aug 2026
- Primary completion
- Feb 2030
- Countries
- 1
01
Overview
A Phase 2 trial of tirzepatide in stimulant use disorder (SUD), obesity, sponsored by UT Southwestern Medical Center. Started Aug 2026; status: active, not recruiting.
02
Drugs
03
Conditions
stimulant use disorder (SUD)obesity
Beyond the preview
Go deeper on NCT07693608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07693608.